Eur Rev Med Pharmacol Sci 2022; 26 (2): 347-349
DOI: 10.26355/eurrev_202201_27858

OAS1 gene, Spike protein variants and persistent COVID-19-related anosmia: may the olfactory disfunction be a harbinger of future neurodegenerative disease?

A. Di Stadio, E. Bernitsas, M. Ralli, C. Severini, M.J. Brenner, C. Angelini

Neuroinflammation Laboratory, UCL Queen Square Neurology, London, UK. ariannadistadio@hotmail.com

Free PDF Download

To cite this article

A. Di Stadio, E. Bernitsas, M. Ralli, C. Severini, M.J. Brenner, C. Angelini
OAS1 gene, Spike protein variants and persistent COVID-19-related anosmia: may the olfactory disfunction be a harbinger of future neurodegenerative disease?

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 2
Pages: 347-349
DOI: 10.26355/eurrev_202201_27858

Keywords Related articles:

  1. Randomized clinical trial “olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin”: preliminary results
  2. CD147 as an alternative binding site for the spike protein on the surface of SARS-CoV-2
  3. Olfactory disfunction and its relation olfactor bulbus volume in Parkinson’s disease
  4. Defining the burden of olfactory dysfunction in COVID-19 patients
  5. SARS-CoV-2: phylogenetic status, mutations and therapeutic research based on spike protein